

STANDARD MEDICARE PART B MANAGEMENT

SEVENFACT (coagulation factor VIIa [recombinant]-jncw)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indication

Sevenfact [coagulation factor VIIa (recombinant)-jncw] is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors.

Limitation of Use: Sevenfact is not indicated for the treatment of patients with congenital Factor VII deficiency.

All other indications will be assessed on an individual basis. Submissions for indications other than those enumerated in this policy should be accompanied by supporting evidence from Medicare approved compendia.

II. CRITERIA FOR INITIAL APPROVAL

A. Hemophilia A with Inhibitors

Authorization of 12 months may be granted for members 12 years of age or older for treatment of hemophilia A with inhibitors (see Appendix) when the inhibitor titer is ≥ 5 Bethesda units per milliliter (BU/mL) or the member has a history of an inhibitor titer ≥ 5 BU.

B. Hemophilia B with Inhibitors

Authorization of 12 months may be granted for members 12 years of age or older for treatment of hemophilia B with inhibitors (see Appendix) when the inhibitor titer is ≥ 5 Bethesda units per milliliter (BU/mL) or the member has a history of an inhibitor titer ≥ 5 BU.

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must be currently receiving therapy with the requested agent.

A. Hemophilia A or B with Inhibitors

Authorization for 12 months may be granted for members 12 years of age or older when all of the following criteria are met:

Reference number(s)
4695-A

1. The member is currently receiving therapy with the requested medication.
2. The requested medication is being used to treat Hemophilia A or B with inhibitors
3. The member is receiving benefit from therapy (e.g., reduced frequency or severity of bleeds).

IV. APPENDIX: Inhibitors - Bethesda Units (BU)

The presence of inhibitors is confirmed by a specific blood test called the Bethesda inhibitor assay.

- High-titer inhibitors:
 - ≥ 5 BU/mL
 - Inhibitors act strongly and quickly neutralize factor
- Low-titer inhibitors:
 - < 5 BU/mL
 - Inhibitors act weakly and slowly neutralize factor

V. SUMMARY OF EVIDENCE

The contents of this policy were created after examining the following resources:

1. The prescribing information for Sevenfact.
2. The available compendium
 - a. National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium
 - b. Micromedex DrugDex
 - c. American Hospital Formulary Service- Drug Information (AHFS-DI)
 - d. Lexi-Drugs
 - e. Clinical Pharmacology
3. WFH Guidelines for the Management of Hemophilia, 3rd edition
4. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders.

After reviewing the information in the above resources, the FDA-approved indications listed in the prescribing information for Sevenfact are covered.

VI. EXPLANATION OF RATIONALE

Support for FDA-approved indications can be found in the manufacturer's prescribing information.

VII. REFERENCES

1. Sevenfact [package insert]. Les Ulis, France: Laboratoire Francais du Fractionnement et des Biotechnologies S.A. (LFB S.A.); April 2020.
2. IBM Micromedex [Internet database]. Ann Arbor, MI: Truven Health Analytics. Updated periodically. Accessed December 3, 2022.
3. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. *Haemophilia*. 2020;26 Suppl 6:1-158. doi:10.1111/hae.14046.
4. National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. Revised March 2022. MASAC Document #272. https://www.hemophilia.org/sites/default/files/document/files/272_Treatment.pdf. Accessed December 3, 2022.